BIO NOTEBOOK: MedImmune's Jallal is key to AstraZeneca's turnaround
This article was originally published in Scrip
A big part of CEO Pascal Soriot’s plan to turn around AstraZeneca lies in the hands of Bahija Jallal, the new head of MedImmune.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.